ENOB
Income statement / Annual
Last year (2025), Enochian Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Enochian Biosciences, Inc.'s net income was -$178.01 M.
See Enochian Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$42.77 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.28 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$37.49 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.88
|
| Research and Development Expenses |
$537.43 K
|
$2.71 M
|
$4.17 T
|
$8.37 M
|
$15.54 M
|
$4.69 M
|
$2.50 M
|
$616.96 K
|
$62.76 K
|
$804.19 K
|
| General & Administrative Expenses |
$17.88 M
|
$24.56 M
|
$15.32 T
|
$14.33 M
|
$7.74 M
|
$7.12 M
|
$8.42 M
|
$4.69 M
|
$2.57 M
|
$1.33 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.88 M
|
$24.56 M
|
$15.32 T
|
$14.33 M
|
$7.74 M
|
$7.12 M
|
$8.42 M
|
$4.69 M
|
$2.57 M
|
$1.33 M
|
| Other Expenses |
$170.55 M
|
$54.37 M
|
$19.07 T
|
$123.00 K
|
$124.00 K
|
$109.00 K
|
$71.71 K
|
-$1.38 M
|
$0.00
|
$119.10 K
|
| Operating Expenses |
$188.97 M
|
$81.64 M
|
$38.56 T
|
$22.83 M
|
$23.40 M
|
$11.92 M
|
$10.99 M
|
$8.17 M
|
$2.65 M
|
$2.16 M
|
| Cost And Expenses |
$0.00
|
$0.00
|
$38.56 T
|
$22.83 M
|
$23.40 M
|
$11.92 M
|
$10.99 M
|
$8.17 M
|
$2.65 M
|
$2.16 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$122.04 K
|
$13.18 K
|
$50.30 K
|
$73.49 K
|
$45.82 K
|
$0.00
|
$0.00
|
| Interest Expense |
$725.68 K
|
-$1.01 M
|
-$580.34 B
|
$372.84 K
|
$379.61 K
|
$104.28 K
|
$0.00
|
$143.26 K
|
$26.26 K
|
$2.36 K
|
| Depreciation & Amortization |
$129.10 K
|
$121.86 K
|
$113.50 B
|
$123.59 B
|
$391.42 K
|
$108.58 K
|
$145.20 K
|
$2.86 M
|
$14.53 K
|
$27.40 K
|
| EBITDA |
-$177.15 M |
-$81.52 M |
-$40.15 T |
-$113.68 T |
-$26.08 M |
-$11.20 M |
-$10.92 M |
-$6.55 M |
-$2.45 M |
-$2.17 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-50.81
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-49.59
|
| Total Other Income/Expenses Net |
$10.96 M
|
$989.12 K
|
-$1.13 T
|
-$90.36 M
|
-$3.45 M
|
$507.41 K
|
-$7.03 M
|
-$1.09 M
|
$192.72 K
|
-$77.10 K
|
| Income Before Tax |
-$178.01 M
|
-$80.65 M
|
-$39.68 T
|
-$113.43 M
|
-$26.85 M
|
-$11.42 M
|
-$18.02 M
|
-$9.26 M
|
-$2.46 M
|
-$2.20 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-51.39
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$125.00 K
|
$104.28 K
|
$7.10 M
|
-$112.00 K
|
-$64.88 K
|
-$463.00 K
|
| Net Income |
-$178.01 M
|
-$80.65 M
|
-$39.68 T
|
-$113.43 M
|
-$26.72 M
|
-$11.52 M
|
-$25.12 M
|
-$9.15 M
|
-$2.39 M
|
-$1.74 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-40.57
|
| EPS |
-1.08 |
-0.84 |
-705301.71 |
-2.16 |
-0.57 |
-0.25 |
-0.67 |
-0.42 |
-0.2 |
-0.18 |
| EPS Diluted |
-1.08 |
-0.84 |
-705301.71 |
-2.16 |
-0.57 |
-0.25 |
-0.67 |
-0.42 |
-0.2 |
-0.18 |
| Weighted Average Shares Out |
$165.06 M
|
$96.25 M
|
$56.27 M
|
$52.53 M
|
$47.17 M
|
$46.33 M
|
$37.55 M
|
$21.94 M
|
$12.27 M
|
$9.53 M
|
| Weighted Average Shares Out Diluted |
$165.06 M
|
$96.25 M
|
$56.27 M
|
$52.53 M
|
$47.17 M
|
$46.33 M
|
$37.55 M
|
$21.94 M
|
$12.27 M
|
$9.53 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
